World's Best Scientists 2026 revealed!

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Medicine 86 14279 13443 7217 6678 422 23039

Ravi Bhatia publications per year

The chart shows the history of publications by Ravi Bhatia between 1973 and 2026, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Ravi Bhatia published across 54 years, from 1973 to 2026, averaging 10.9 papers a year. Output peaked at 49 publications in 2024. 50 of the 588 publications appeared in the last two years.

No. of publications
10 20 30 40
Bar chart. Horizontal axis: year, 1973 to 2026. Vertical axis: number of publications, 0 to 49. Peak 49 publications in 2024. 1973: 2 publications 1974: 0 publications 1975: 0 publications 1976: 2 publications 1977: 4 publications 1978: 1 publication 1979: 0 publications 1980: 0 publications 1981: 1 publication 1982: 0 publications 1983: 2 publications 1984: 4 publications 1985: 4 publications 1986: 1 publication 1987: 2 publications 1988: 1 publication 1989: 4 publications 1990: 2 publications 1991: 0 publications 1992: 1 publication 1993: 1 publication 1994: 3 publications 1995: 6 publications 1996: 3 publications 1997: 5 publications 1998: 7 publications 1999: 5 publications 2000: 7 publications 2001: 2 publications 2002: 2 publications 2003: 3 publications 2004: 13 publications 2005: 16 publications 2006: 10 publications 2007: 26 publications 2008: 14 publications 2009: 17 publications 2010: 23 publications 2011: 20 publications 2012: 24 publications 2013: 25 publications 2014: 27 publications 2015: 16 publications 2016: 23 publications 2017: 17 publications 2018: 27 publications 2019: 13 publications 2020: 12 publications 2021: 20 publications 2022: 39 publications 2023: 32 publications 2024: 49 publications 2025: 49 publications 2026: 1 publication
1973 2026

588 publications in total across all disciplines

View publications per year as a table
Ravi Bhatia: publications per year, 1973 to 2026
Year Publications
1973 2
1974 0
1975 0
1976 2
1977 4
1978 1
1979 0
1980 0
1981 1
1982 0
1983 2
1984 4
1985 4
1986 1
1987 2
1988 1
1989 4
1990 2
1991 0
1992 1
1993 1
1994 3
1995 6
1996 3
1997 5
1998 7
1999 5
2000 7
2001 2
2002 2
2003 3
2004 13
2005 16
2006 10
2007 26
2008 14
2009 17
2010 23
2011 20
2012 24
2013 25
2014 27
2015 16
2016 23
2017 17
2018 27
2019 13
2020 12
2021 20
2022 39
2023 32
2024 49
2025 49
2026 1
Total 588
Download as CSV

Ravi Bhatia publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Ravi Bhatia sits on this spectrum.

No. of scientists
200 400 600 800
Bar chart with 86 bars. Horizontal axis: publications, 101–120 to 1,796+. Vertical axis: number of scientists, 0 to 922. Most scientists, 922, have 341–360 publications. The last bar groups every scientist with 1,796 publications or more. The highlighted bar, 421–440 publications, is where this scientist sits. 101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101–120 publications 1,796+

This scientist: 422 publications — 43rd percentile

43% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

View publications distribution as a table
Number of Medicine scientists by publication count, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
Publications Scientists This scientist
101–120 5
121–140 26
141–160 73
161–180 155
181–200 230
201–220 363
221–240 487
241–260 545
261–280 722
281–300 768
301–320 834
321–340 895
341–360 922
361–380 838
381–400 861
401–420 918
421–440 806 422
441–460 771
461–480 751
481–500 713
501–520 617
521–540 610
541–560 537
561–580 504
581–600 509
601–620 396
621–640 386
641–660 371
661–680 340
681–700 336
701–720 307
721–740 259
741–760 230
761–780 228
781–800 217
801–820 204
821–840 186
841–860 177
861–880 155
881–900 139
901–920 145
921–940 116
941–960 133
961–980 91
981–1,000 96
1,001–1,020 77
1,021–1,040 70
1,041–1,060 63
1,061–1,080 77
1,081–1,100 49
1,101–1,120 54
1,121–1,140 49
1,141–1,160 51
1,161–1,180 35
1,181–1,200 39
1,201–1,220 26
1,221–1,240 37
1,241–1,260 36
1,261–1,280 27
1,281–1,300 32
1,301–1,320 28
1,321–1,340 17
1,341–1,360 30
1,361–1,380 28
1,381–1,400 17
1,401–1,420 21
1,421–1,440 15
1,441–1,460 12
1,461–1,480 12
1,481–1,500 18
1,501–1,520 14
1,521–1,540 17
1,541–1,560 15
1,561–1,580 6
1,581–1,600 2
1,601–1,620 12
1,621–1,640 11
1,641–1,660 8
1,661–1,680 5
1,681–1,700 5
1,701–1,720 10
1,721–1,740 12
1,741–1,760 14
1,761–1,780 6
1,781–1,795 5
1,796+ 100
Download as CSV

Ravi Bhatia D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Ravi Bhatia sits on this spectrum.

No. of scientists
250 500 750 1,000
Bar chart with 75 bars. Horizontal axis: D-Index, 70–71 to 217+. Vertical axis: number of scientists, 0 to 1,027. Most scientists, 1,027, have 82–83 D-Index. The last bar groups every scientist with 217 D-Index or more. The highlighted bar, 86–87 D-Index, is where this scientist sits. 70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70–71 D-Index 217+

This scientist: 86 D-Index — 31st percentile

31% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

View D-Index distribution as a table
Number of Medicine scientists by D-index, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
D-Index Scientists This scientist
70–71 226
72–73 391
74–75 574
76–77 730
78–79 891
80–81 972
82–83 1,027
84–85 1,003
86–87 960 86
88–89 970
90–91 922
92–93 839
94–95 808
96–97 779
98–99 668
100–101 611
102–103 630
104–105 513
106–107 541
108–109 445
110–111 429
112–113 399
114–115 393
116–117 318
118–119 302
120–121 287
122–123 255
124–125 256
126–127 252
128–129 230
130–131 179
132–133 168
134–135 163
136–137 159
138–139 134
140–141 134
142–143 118
144–145 109
146–147 106
148–149 74
150–151 79
152–153 80
154–155 87
156–157 57
158–159 74
160–161 69
162–163 60
164–165 53
166–167 39
168–169 42
170–171 32
172–173 39
174–175 40
176–177 28
178–179 19
180–181 23
182–183 31
184–185 18
186–187 20
188–189 22
190–191 13
192–193 21
194–195 12
196–197 12
198–199 14
200–201 15
202–203 13
204–205 10
206–207 8
208–209 4
210–211 12
212–213 11
214–215 10
216 4
217+ 98
Download as CSV

Overview

What is he best known for?

The fields of study he is best known for:

  • Gene
  • Cancer
  • Internal medicine

Ravi Bhatia mainly focuses on Cancer research, Chronic myelogenous leukemia, Leukemia, Stem cell and Imatinib mesylate. The various areas that Ravi Bhatia examines in his Cancer research study include Haematopoiesis, Progenitor cell, Tyrosine kinase, Kinase activity and Bone marrow. His Chronic myelogenous leukemia research is multidisciplinary, incorporating elements of K562 cells and Philadelphia chromosome.

His research integrates issues of Myeloid, Myeloid leukemia and Transplantation in his study of Leukemia. He does research in Stem cell, focusing on Cancer stem cell specifically. His Imatinib mesylate study integrates concerns from other disciplines, such as breakpoint cluster region and ABL.

His most cited work include:

  • Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance (638 citations)
  • Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. (492 citations)
  • miR-328 Functions as an RNA Decoy to Modulate hnRNP E2 Regulation of mRNA Translation in Leukemic Blasts (422 citations)

What are the main themes of his work throughout his whole career to date?

His primary areas of study are Cancer research, Stem cell, Progenitor cell, Immunology and Leukemia. The concepts of his Cancer research study are interwoven with issues in Chronic myelogenous leukemia and Tyrosine kinase, ABL. His work investigates the relationship between Chronic myelogenous leukemia and topics such as Integrin that intersect with problems in Cell adhesion and Cell adhesion molecule.

His Stem cell study combines topics in areas such as Myeloid and Bone marrow. His biological study spans a wide range of topics, including Cancer cell, Molecular biology, Apoptosis and CD38. His Leukemia study is related to the wider topic of Internal medicine.

He most often published in these fields:

  • Cancer research (47.45%)
  • Stem cell (34.18%)
  • Progenitor cell (32.14%)

What were the highlights of his more recent work (between 2015-2021)?

  • Cancer research (47.45%)
  • Stem cell (34.18%)
  • Internal medicine (21.17%)

In recent papers he was focusing on the following fields of study:

Ravi Bhatia mostly deals with Cancer research, Stem cell, Internal medicine, Leukemia and Myeloid leukemia. His research integrates issues of Cell growth, Progenitor cell, Tyrosine kinase, ABL and Chronic myelogenous leukemia in his study of Cancer research. His research in Stem cell intersects with topics in Immunology and Bone marrow.

His work in Internal medicine tackles topics such as Oncology which are related to areas like Philadelphia chromosome, Discontinuation, Polycythemia vera, Risk stratification and Essential thrombocythemia. His study in the field of Myelogenous also crosses realms of PARP1. His Myeloid leukemia study combines topics from a wide range of disciplines, such as Hematopoietic stem cell transplantation, DNA methylation, CXCR4, CD33 and Drug resistance.

Between 2015 and 2021, his most popular works were:

  • High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. (172 citations)
  • Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma (162 citations)
  • Chronic myeloid leukemia, version 1.2019 (137 citations)

In his most recent research, the most cited papers focused on:

  • Gene
  • Cancer
  • Internal medicine

Leukemia, Cancer research, Stem cell, Myeloid leukemia and Internal medicine are his primary areas of study. His study with Leukemia involves better knowledge in Immunology. The Cancer research study combines topics in areas such as Haematopoiesis, Bone marrow, Tyrosine-kinase inhibitor and DNA repair.

His study in Stem cell is interdisciplinary in nature, drawing from both Chronic myelogenous leukemia and Tyrosine kinase, Nilotinib. His Internal medicine research incorporates themes from Philadelphia chromosome and Oncology. Ravi Bhatia studied Hematopoietic stem cell and breakpoint cluster region that intersect with ABL.

Best Publications

  • Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

    Hagop M. Kantarjian;Francis Giles;Norbert Gattermann;Kapil Bhalla

  • Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.

    Ravi Bhatia;Melissa Holtz;Ning Niu;Rachel Gray

  • miR-328 Functions as an RNA Decoy to Modulate hnRNP E2 Regulation of mRNA Translation in Leukemic Blasts

    Anna M. Eiring;Jason G. Harb;Paolo Neviani;Christopher Garton

  • Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival

    Ashley Hamilton;G. Vignir Helgason;Mirle Schemionek;Bin Zhang

  • PAX5 -driven subtypes of B-progenitor acute lymphoblastic leukemia

    Zhaohui Gu;Michelle L. Churchman;Kathryn G. Roberts;Ian Moore

  • Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib

    Ling Li;Lisheng Wang;Liang Li;Zhiqiang Wang

  • High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.

    Kathryn G. Roberts;Zhaohui Gu;Debbie Payne-Turner;Kelly McCastlain

  • T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia

    Armen Mardiros;Cedric Dos Santos;Tinisha McDonald;Christine E. Brown

  • Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma

    Christopher J Gibson;R Coleman Lindsley;Vatche Tchekmedyian;Brenton G Mar

  • Altered Microenvironmental Regulation of Leukemic and Normal Stem Cells in Chronic Myelogenous Leukemia

    Bin Zhang;Yin Wei Ho;Qin Huang;Takahiro Maeda

  • Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion

    B. Kumar;M. Garcia;L. Weng;X. Jung

  • Solid Cancers After Bone Marrow Transplantation

    Smita Bhatia;Andrew D. Louie;Ravi Bhatia;Margaret R. O’Donnell

  • Stem cell quiescence.

    Ling Li;Ravi Bhatia

  • Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors.

    Amrita Krishnan;Smita Bhatia;Marilyn L. Slovak;Daniel A. Arber

  • Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation.

    Melissa S. Holtz;Marilyn L. Slovak;Feiyu Zhang;Charles L. Sawyers

  • Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment

    Su Chu;Helen Xu;Helen Xu;Neil P. Shah;Neil P. Shah;David S. Snyder;David S. Snyder

  • Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate

    Bin Zhang;Adam C. Strauss;Su Chu;Min Li

  • Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt–β-catenin signaling

    Bin Zhang;Min Li;Tinisha McDonald;Tessa L. Holyoake

  • Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment.

    Su Chu;Tinisha McDonald;Allen Lin;Sujata Chakraborty

  • BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Commentary

    Ravi Bhatia;Mateusz Koptyra;Rafal Falinski;Michal O. Nowicki

Frequent Co-Authors

Stephen J. Forman
Stephen J. Forman City Of Hope National Medical Center
Smita Bhatia
Smita Bhatia University of Alabama at Birmingham
Tessa L. Holyoake
Tessa L. Holyoake University of Glasgow
Jerald P. Radich
Jerald P. Radich Fred Hutchinson Cancer Research Center
Jorge E. Cortes
Jorge E. Cortes Augusta University
Philip B. McGlave
Philip B. McGlave University of Minnesota
Daniel J. Weisdorf
Daniel J. Weisdorf University of Minnesota
Arturo Molina
Arturo Molina Sutro Biopharma
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medical careers in the USA goes beyond traditional medicine programs. Many students choose alternative health pathways, which often begin with flexible online degrees and certifications. For example, pursuing a career in medical billing or coding is a practical entry point to healthcare. Students should compare medical coding certification cost to find programs that fit their budget and career plans.

Nursing remains a popular and highly rewarding path. Aspiring nurse practitioners can reduce expenses by seeking out the cheapest online fnp programs, many of which offer quality education and flexibility. Those starting their nursing education often begin with online nursing courses that prepare them for entry-level roles and further study.

For advanced professionals, pursuing an online phd nursing programs can unlock opportunities in research, education, and leadership. Each pathway has different time commitments, tuition costs, and career outcomes, so prospective students should carefully research options that match their professional goals and financial resources.

Best Scientists Citing Ravi Bhatia

Trending Scientists

Recently Published Articles